JP2017513902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513902A5 JP2017513902A5 JP2016564162A JP2016564162A JP2017513902A5 JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5 JP 2016564162 A JP2016564162 A JP 2016564162A JP 2016564162 A JP2016564162 A JP 2016564162A JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5
- Authority
- JP
- Japan
- Prior art keywords
- fcrn
- afp
- pharmaceutical composition
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100014838 FCGRT Human genes 0.000 claims 18
- 101710003435 FCGRT Proteins 0.000 claims 18
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 18
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000038129 antigens Human genes 0.000 claims 5
- 108091007172 antigens Proteins 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 101700000292 H161 Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 101700004523 ehaG Proteins 0.000 claims 2
- 210000000013 Bile Ducts Anatomy 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 102000004641 Fetal Proteins Human genes 0.000 claims 1
- 108010003471 Fetal Proteins Proteins 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 claims 1
- 208000001608 Teratocarcinoma Diseases 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Claims (10)
- アルファ−フェトプロテイン（AFP）とFcRnとの結合を阻害する、AFP-FcRnの阻害剤；および
薬学的に許容される担体
を含む、AFPレベルの上昇に関連している疾患または障害における、FcRnとアルファ−フェトプロテイン（AFP）との相互作用を阻害するまたは低下させることに使用するための薬学的組成物。 - AFP-FcRnの阻害剤が、FcRn上のAFP結合部位を阻害または遮断する、請求項1に記載の薬学的組成物。
- AFP-FcRnの阻害剤が、抗体またはその抗原結合フラグメントである、請求項1または2に記載の薬学的組成物。
- 抗体またはその抗原結合フラグメントが、キメラ抗体、ヒト化抗体、または完全ヒト抗体もしくはその抗原結合フラグメントである、請求項3に記載の薬学的組成物。
- AFP-FcRnの阻害剤が、野生型AFPのT451Iおよび／またはD536V多型を含む、請求項1〜4のいずれか一項に記載の薬学的組成物。
- AFP-FcRnの阻害剤が、以下においてAFPとFcRnとの間の結合を阻害する、請求項1〜5のいずれか一項に記載の薬学的組成物；
(a) AFPのY521および／またはV522と、FcRnのR42、
(b) AFPのP492と、FcRnのR69、
(c) AFPのQ441および／またはV493と、FcRnのE44、
(d) AFPのH534および／またはE589と、FcRnのN173、
(e) AFPの疎水性コアと、FcRn、
(f) AFPのL484、V493、V497、および／またはF512と、FcRnのV57、W59、および／またはW61、
(g) AFPのT443と、FcRnのE62および／またはW59、
(h) AFPのD529と、FcRnのS230、
(i) AFPのS527および／またはD528と、FcRnと複合体化したβ2mのE50および／または67Y、
(j) AFPのR604と、FcRnと複合体化したβ2mのE50でのカルボニル酸素、
(k) AFPのQ597と、FcRnと複合体化したβ2mのE69、
(l) AFPのE106と、FcRnのH161、
(m) AFPのS135と、FcRnのH161、および／または
(n) AFPのF531、F533、F552、および／またはF575と、FcRnのW53。 - がんを有する、またはがんと診断されている対象に投与するための、請求項1〜6のいずれか一項に記載の薬学的組成物。
- 原始起源のがんもしくは腫瘍、肝臓由来の腫瘍、例えば肝臓がん、胆管由来の腫瘍、例えば胆管がん、胃がん、膵臓がん、または奇形がんを有する、またはそれと診断されている対象に投与するための、請求項1〜7のいずれか一項に記載の薬学的組成物。
- 抗がん治療剤または抗がん剤とともに対象に投与するための、請求項1〜8のいずれか一項に記載の薬学的組成物。
- 腫瘍抗原またはがん抗原とともに投与するための、請求項1〜9のいずれか一項に記載の薬学的組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984252P | 2014-04-25 | 2014-04-25 | |
| US61/984,252 | 2014-04-25 | ||
| US201562101539P | 2015-01-09 | 2015-01-09 | |
| US62/101,539 | 2015-01-09 | ||
| PCT/US2015/026860 WO2015164364A2 (en) | 2014-04-25 | 2015-04-21 | Methods to manipulate alpha-fetoprotein (afp) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513902A JP2017513902A (ja) | 2017-06-01 |
| JP2017513902A5 true JP2017513902A5 (ja) | 2018-06-07 |
| JP6792454B2 JP6792454B2 (ja) | 2020-11-25 |
Family
ID=54333408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564162A Active JP6792454B2 (ja) | 2014-04-25 | 2015-04-21 | アルファ−フェトプロテイン（ａｆｐ）を操作するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20170044257A1 (ja) |
| EP (2) | EP3804745A1 (ja) |
| JP (1) | JP6792454B2 (ja) |
| AU (1) | AU2015249946A1 (ja) |
| CA (1) | CA2983794A1 (ja) |
| WO (1) | WO2015164364A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520575D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN107561284B (zh) * | 2016-03-25 | 2019-01-29 | 江苏迈源生物科技有限公司 | 易于操作的甲胎蛋白试剂盒 |
| CA3024421A1 (en) | 2016-04-25 | 2017-11-02 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| EP3512551A4 (en) * | 2016-09-16 | 2020-08-05 | The Brigham and Women's Hospital, Inc. | BLOCUS OF INTERACTIONS OF ALPHAF TOPROTEIN (AFP) WITH MOLECULES ASSOCIATED WITH MICROGLOBULIN BETA2 |
| CN106916222B (zh) * | 2017-04-18 | 2020-05-05 | 河北渤腾医药技术有限公司 | 甲胎蛋白检测试剂盒 |
| WO2020037213A1 (en) * | 2018-08-17 | 2020-02-20 | Genentech, Inc. | In vitro transcytosis assay |
| WO2023198806A1 (en) * | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | New class of molecules for selective clearance of antibody |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4747825A (en) | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4948592A (en) | 1986-05-09 | 1990-08-14 | Alza Corporation | Pulsed drug delivery |
| US4723958A (en) | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4965251A (en) | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| JPH06105020B2 (ja) | 1992-06-09 | 1994-12-21 | ホッペ・アーゲー | ラッチ及びロックアップシステム |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5403590A (en) | 1992-12-21 | 1995-04-04 | New England Deaconess Hospital Corporation | Method of pulsatile drug infusion |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US20020110556A1 (en) * | 1997-08-15 | 2002-08-15 | Moro Ricardo J. | Detection and treatment of cancer |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JPH11511847A (ja) * | 1995-09-18 | 1999-10-12 | ジェイ． モロ，リカード | 癌の検出及び処理 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| CA2286879C (en) | 1997-04-14 | 2003-12-16 | Peter Kufer | Novel method for the production of anti-human antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| WO2006118772A2 (en) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| WO2010138814A2 (en) * | 2009-05-29 | 2010-12-02 | The Brigham And Women's Hospital, Inc. | Disrupting fcrn-albumin interactions |
-
2015
- 2015-04-21 JP JP2016564162A patent/JP6792454B2/ja active Active
- 2015-04-21 WO PCT/US2015/026860 patent/WO2015164364A2/en active Application Filing
- 2015-04-21 EP EP20193844.6A patent/EP3804745A1/en active Pending
- 2015-04-21 CA CA2983794A patent/CA2983794A1/en not_active Abandoned
- 2015-04-21 AU AU2015249946A patent/AU2015249946A1/en not_active Abandoned
- 2015-04-21 EP EP15783202.3A patent/EP3148567A4/en not_active Ceased
- 2015-04-21 US US15/306,665 patent/US20170044257A1/en not_active Abandoned
-
2019
- 2019-02-25 US US16/284,005 patent/US20200010543A1/en active Pending
- 2019-10-01 US US16/590,164 patent/US20200031928A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513902A5 (ja) | ||
| HRP20210122T1 (hr) | Protutijela usmjerena protiv programirane smrti-1 (pd-1) | |
| JP2014240385A5 (ja) | ||
| JP2015534580A5 (ja) | ||
| JP2016502504A5 (ja) | ||
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2012046518A5 (ja) | ||
| AU2015219495B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
| MX2023001299A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| JP2015534577A5 (ja) | ||
| RU2017115773A (ru) | 17альфа-бензоат кортексолона для применения в лечении опухолей | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| JP2008154589A5 (ja) | ||
| UA118255C2 (uk) | Композиція, яка містить антитіло до cd38 і леналідомід | |
| JP2017523140A5 (ja) | ||
| EA201370105A1 (ru) | Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a) | |
| EA201190116A1 (ru) | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 | |
| JP2018515137A5 (ja) | ||
| JP2017527582A5 (ja) | ||
| JP2016183163A5 (ja) | ||
| WO2015191568A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| JP2015524414A5 (ja) | ||
| JP2015519347A5 (ja) |